臨床泌尿器科70巻6号

2016年05月発行

特集 前立腺肥大症の薬物療法─使い分けのポイント

〈第一選択薬〉

サブタイプを考慮したα₁遮断薬の選択

著者： 秦淳也¹ 赤井畑秀則¹ 小島祥敬¹

所属機関： ¹福島県立医科大学医学部泌尿器科学講座

ページ範囲：P.398 - P.403

文献概要

▶ポイント

・ヒト前立腺組織には主にα_1a受容体とα_1d受容体が多く発現しており，α_1b受容体の関与は少ない．

・各臓器のα₁受容体サブタイプの特徴，α₁遮断薬のサブタイプ選択性を考慮することが，より効率的なα₁遮断薬の選択に重要である．

・患者の遺伝的背景が，α₁遮断薬の効果を規定する因子として重要である．

参考文献

1） Kojima Y, Kubota Y, Sasaki S, et al : Translational pharmacology in aging men with benign prostatic hyperplasia : molecular and clinical approaches to alpha1-adrenoceptors. Curr Aging Sci 2 : 223─239, 2009

2） Kojima Y, Sasaki S, Shinoura H, et al : Quantification of alpha1-adrenoceptor subtypes by real-time RT-PCR and correlation with age and prostate volume in benign prostatic hyperplasia patients. Prostate 66 : 761─767, 2006

3） 日本泌尿器科学会 （編） : 前立腺肥大症診療ガイドライン. pp98─99, リッチヒルメディカル, 東京, 2011

4） Kojima Y, Sasaki S, Imura M, et al : Tamslosin reduces nighttime urine production in benign prostatic hyperplasia patients with nocturnal polyuria : a prospective open-label long-term study using frequency-volume chart. Neurol Urodyn 31 : 80─85, 2012

5） Kojima Y, Hayase M, Sasaki S, et al : New pharmacologic horizons in the treatment antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Jpn J Pharmacol 79 : 447─454, 1999

6） Hisaue S, Furuya R, Itoh N, et al : Ejaculatory disorder caused by alpha-1 aderenoceptor antagonist is not retrograde ejaculateion but a loss seminal emission. Int J Urol 13 : 1311─1316, 2006

7） Bell CM, Hatch WV, Fischer HD, et al : Association between tamsulosin and serious ophthalmic adverse events in order men following contaract surgery. JAMA 301 : 1991─1996, 2009

8） McConnell JD, Roehrborn CG, Bautista OM, et al : The long-term effect of doxazosin, finesteride, and combination therapy on the clinical progeression of benign prostatic hyperplasia. N Engl J Med 349 : 2387─2398, 2003

9） Roehrborn CG, Siami P, Barkin J, et al : The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia : 4-year results from the CombAT study. Eur Urol 57 : 123─131, 2010

10） Schulman CC, Lock TMTW, Buzelin JM, et al : Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J Urol 166 : 1358─1363, 2001

11） Nishino Y, Masue T, Miwa K, et al : Comparison of two alpha1-adrenoceptor antagonists, naftpidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia : a randomized crossover study. BJU Int 97 : 747─751, 2006

12） Kawabe K, Yoshida M, Homma Y, et al : Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia : results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98 : 1019─1024, 2006

13） Masumori N, Tsukamoto T, Iwasawa A, et al : Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia : comparison of naftpidil and tamsulosin in a randomized multicenter study. Urol Int 83 : 49─54, 2009

14） Takei R, Ikegaki I, Shibata K, et al : Naftpidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Jpn J Pharmacol 79 : 447─454, 1999

15） Kojima Y, Sasaki S, Kubota Y, et al : Up-regulation of α1a and α1d-adrenoceptors in the prostate by administration of subtype selective α1-adrenoceptor antagonist tamsulosin in patients with benign prostatic hyperplasia. J Urol 186 : 1530─1536, 2011

16） Takata R, Matsuda K, Sugimura J, et al : Impact of four loci on serum tamsulosin hydrochloride concentration. J Hum Genet 58 : 21─26, 2013